Notícias e Atividades da Emergent BioSolutions

Emergent BioSolutions é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Emergent BioSolutions é uma empresa listada sob o símbolo EBS (US).

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Emergent BioSolutions

• Joseph Papa, Chief Executive Officer and Director
• Zsolt Harsanyi, Chairman of the Board
• Kathryn Zoon, Director

Recentes movimentos de executivos em Emergent BioSolutions

• Simon Lowry, ingressou na Companhia como Chief Medical Officer and Head of Research and Development  (Notícia publicada em 5 de novembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Emergent BioSolutions.

Emergent BioSolutions possui 1.824 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Roche (Suíça).

Popular M&A news in Farmacêutica

• Cyclo Therapeutics adquiriu Rafael Holdings (publicado em 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado em 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Jean-Michel Demeure - Vice President, Finance Global Operations da Sanofi

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Emergent BioSolutions

• Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency | Emergent BioSolutions Inc.
• Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position | Emergent BioSolutions Inc.
• Emergent BioSolutions Reports Financial Results for Second Quarter 2023 | Emergent BioSolutions Inc.
• Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola | Emergent BioSolutions Inc.
• Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use | Emergent BioSolutions Inc.
• Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023 | Emergent BioSolutions Inc.
• Emergent BioSolutions Announces CEO Transition | Emergent BioSolutions Inc.
• Emergent BioSolutions Reports Financial Results For First Quarter 2023 | Emergent BioSolutions Inc.
• News | Emergent BioSolutions Inc.
• Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic | Emergent BioSolutions Inc.
• View more press releases Close

Redes sociais sobre Emergent BioSolutions

• Emergent BioSolutions na Wikipedia, Google News e Yahoo Finance
• Emergent BioSolutions na LinkedIn, Twitter e YouTube